Purpose: To assess the role of hyperbaric oxygen therapy (HBOT) in the management of recurrent pterygium.

Methods: Thirty-nine eyes with recurrent pterygium were treated with surgical excision and limbal conjunctival autograft, followed by a course of HBOT. Patients were followed for development of recurrence.

Results: Of the 39 eyes, 18 had a known history of exposure to beta radiation or mitomycin C. The mean duration of follow-up in this group was 23.1 months. A single recurrence was noted in this group. For the remaining 21 eyes, the mean duration of follow-up was 19.4 months. No recurrences were recorded in this group. No significant complications from HBOT were recorded.

Conclusions: The use of HBOT together with excision and limbal conjunctival autograft for recurrent pterygium is associated with a low recurrence rate. Adjuvant HBOT should be considered in the surgical management of recurrent pterygium.

Download full-text PDF

Source
http://dx.doi.org/10.1097/ICO.0b013e3181da58a4DOI Listing

Publication Analysis

Top Keywords

recurrent pterygium
16
limbal conjunctival
12
management recurrent
12
hyperbaric oxygen
8
oxygen therapy
8
excision limbal
8
conjunctival autograft
8
duration follow-up
8
recurrent
5
hbot
5

Similar Publications

Introduction And Importance: Conjunctival squamous cell carcinoma (SCC) is the most advanced form of ocular surface squamous neoplasia (OSSN), with varying incidence rates influenced by factors such as age, UV exposure, and occupation. Early detection is crucial, but misdiagnosis is common, especially when SCC mimics benign conditions like pterygium.

Case Presentation: An 83-year-old Caucasian male farmer presented with a rapidly enlarging nasal limbal lesion, initially misdiagnosed as pterygium.

View Article and Find Full Text PDF

We describe a novel technique for recurrent pterygium and assess the advantage of properties of extended tenonectomy, amniotic membrane transplantation, and limbal epithelial transplantation in terms of recurrence rate, postoperative symptoms, postoperative orthoptics, and other complications. A total of nine eyes with recurrent pterygium underwent PERMISLET, i.e.

View Article and Find Full Text PDF

Inhibition of pterygium cell fibrosis by the Rho kinase inhibitor.

Sci Rep

December 2024

Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, RM305v, 1160 W. Michigan St., Indianapolis, IN, 46202, USA.

Pterygium is an ocular disease in which the conjunctival tissue invades the cornea. When the pterygium tissue reaches the pupillary region, the visual function of the patient is affected. Currently, surgical removal is the only effective treatment.

View Article and Find Full Text PDF

Comparison of Biomarkers Playing a Role in Pterygium Development in Pterygium and Recurrent Pterygium Tissues.

Diagnostics (Basel)

November 2024

Department of Medical Laboratory Techniques, Ataturk Vocational School of Health Services, Afyonkarahisar Health Sciences University, 03030 Afyonkarahisar, Turkey.

Pterygium is a nonneoplastic elastotic degeneration characterized by subepithelial growth. It manifests as an ocular lesion originating from the bulbar conjunctiva, extending to the corneal surface, and reaching the visual axis in some cases. Although the exact cause is unknown, prolonged exposure to ultraviolet radiation is considered the most significant contributing factor.

View Article and Find Full Text PDF

Purpose: To assess the effectiveness and safety of the "hydro-fluorescein" adjunct technique for primary pterygium removal.

Design/methods: A non-randomized prospective study was conducted for various types of pterygium excision with superior bulbar conjunctival autograft (CAG) and fibrin glue. We introduced fluorescein staining to ensure thorough elimination of the Tenon tissue around the bare sclera area and the CAG.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!